by Lupus Foundation, Ohio | Feb 3, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC), self-administration of Saphnelo (anifrolumab). AstraZeneca has...
by Lupus Foundation, Ohio | Feb 3, 2026 | Lupus Foundation of America, News & Events
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM) and systemic lupus erythematosus...
by | Feb 1, 2026 | Lupus Foundation of America
For people living with lupus—especially Black women, who face higher rates of the disease and more severe symptoms—-Black History Month serves as a reminder to actively amplify Black voices, share stories and raise awareness throughout the year. This month, we’re...
by | Feb 1, 2026 | Lupus Foundation of America
Black History Month serves as a reminder to actively amplify Black voices, share stories and raise awareness throughout the year. This month, we’re featuring Danielle Storr, a Black lupus warrior who embodies resilience, strength and leadership.This post was...
by Lupus Foundation, Ohio | Jan 30, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE, a chronic autoimmune skin disease). This designation is given only to...
by | Jan 26, 2026 | Lupus Foundation of America
Because lupus is a complex and highly individualized disease, treatment guidelines play an important role in helping patients and doctors make treatment plans. As Dr. Aranow explains, “Treatment guidelines are just that: They’re guidelines to provide state of the art...
